Evidence-based data on long-term patient- reported Health-Related Quality of Life (HRQoL) in AML survivors, regardless of their treatment in the setting of a randomized controlled trial (RCT) or not, is sparse. The paucity of available evidence shows that shortly after diagnosis and during the course of conventional chemotherapy, physical, psychological, emotional well-being and sexual functions are adversely affected by the disease itself and by the treatment. Significant improvements of HRQoL might be observed over time, paralleling the normalization of bone marrow function and completion of treatment. However, there is still paucity of empirical data in AML patients. With this project, we aim to gather unique knowledge on survivorship issues in AML patients treated both in RCTs and in routine care settings.
30 European Centers (Italian and non-Italian Centers) have already enrolled 225 AML survivors. Study recruitment has been early closed on February 28th, 2022 due to COVID-19 related low accrual rate.
The study recruitment has been stopped in February 2022: potential further participants are not currently being recruited or enrolled.
Ongoing data validation and analysis (planned to start in July, 2022)
All those interested in collaboration might want to contact the PI.
Prof. Fabio Efficace
Head, Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center, Rome, Italy.
University of Liège Liège, Belgium
This study will investigate Patient-Reported Outcomes, such as Quality of Life (QoL), in long-term AML survivors. It will include a large group of patients who received diagnosis of AML and survived at least 5 years from diagnosis.
All participants will be invited to participate through their hematologist and will be asked to complete a set of questionnaires.